

# NICE

## Cinacalcet – Appraisal Consultation Document (2)

- 1.1 Cinacalcet hydrochloride is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.
- 1.2 Cinacalcet hydrochloride is recommended only in those patients with refractory secondary hyperparathyroidism (including those with calciphylaxis):
- who have 'very uncontrolled' plasma levels of intact parathyroid hormone (defined as greater than 85 pmol/litre [800 pg/ml]) that are refractory to standard therapy and
  - in whom surgical parathyroidectomy is contraindicated.

Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma level of intact parathyroid hormone of 30% or more is seen after 3 months' treatment.

### **Kidney Alliance Response**

**The Kidney Alliance welcomes the amendments to the recommendations regarding cinacalcet.**

**The Alliance is comfortable with 1.1 which recommends that the routine treatment of secondary hyperparathyroidism should continue as currently with the use of vitamin D preparations and phosphate binders – standard therapy.**

**The Alliance welcomes the recommendation to allow a trial of cinacalcet to those patients who's disease can no longer be controlled by standard therapy and in whom parathyroidectomy is contraindicated.**

**The Alliance believes that the recommendation could be improved if the word contraindicated was replaced by "in those patients in whom attempted parathyroidectomy is considered a last resort by the clinical team".**

**Given the logistics of PTH measurement and the need for incremental dosing the KA would welcome an extension of the "trial period" to 4 months.**